Anti-APT-2 antibody

• WB

Unknown

Western blot - Anti-APT-2 antibody (AB151578)

All lanes:

Western blot - Anti-APT-2 antibody (ab151578) at 1/1000 dilution

Lane 1:

HepG2 cell lysate at 30 µg

Lane 2:

Raji cell lysate at 30 µg

Predicted band size: 24 kDa

false

• WB

CiteAb

Western blot - Anti-APT-2 antibody (AB151578)

APT-2 western blot using anti-APT-2 antibody ab151578. Publication image and figure legend from Vujic, I., Sanlorenzo, M., et al., 2016, Oncotarget, PubMed 26771141.

ab151578 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab151578 please see the product overview.

siRNA knock down of APT-1 and APT-2 in NRAS and BRAF mutant melanoma(a) and (b) melanoma cells with indicated mutations were transfected with APT-1 or APT-2 targeting siRNA pools (siAPT1, siAPT2) or their combination and compared to cells transfected with a non-targeting siRNA pool (concentration 100nM, incubation 72hrs). a. Immunoblots after APT-1, APT-2 or dual knock down. Densitometry values for APT-1 and APT-2 show the percentage of protein expression following siRNA treatment. No relevant changes in NRAS downstream effectors are seen following APT-1, APT-2 or dual knock down. b. Bar graphs depicting viable cells after APT-1, APT-2 or dual knock down. Analyses revealed no significant differences in cell viability in NRAS and BRAF mutant melanoma cells (incubation 72hrs, n > 3, error bars represent SD)

false